Skip to content
Inciteful Med

A Proactive Path: Standard of Care and New Treatments

Last updated:

Treatment for Rett syndrome combines multidisciplinary therapies with proactive symptom management. Trofinetide (DAYBUE) is the first FDA-approved medication for patients 2 and older, while promising gene therapies targeting the MECP2 gene are currently in clinical trials.

Key Takeaways

  • • Trofinetide (DAYBUE) is the first FDA-approved medication for Rett syndrome in patients aged 2 and older.
  • • A multidisciplinary approach involving physical, occupational, and speech therapy is the gold standard of care.
  • • Augmentative and Alternative Communication (AAC), particularly eye-tracking devices, is vital for helping patients express their needs.
  • • Proactive management of comorbidities like epilepsy, gastrointestinal issues, and scoliosis is essential for patient comfort.
  • • Gene therapy clinical trials are actively investigating ways to deliver a healthy MECP2 gene into brain cells.

Managing Rett syndrome is no longer just about waiting and watching. While there is not yet a cure, the landscape of care has shifted from purely supportive to actively therapeutic. Today, treatment involves a combination of the first FDA-approved medication, intensive multidisciplinary therapies, and a proactive approach to managing the “side-effects” of the syndrome itself [1][2].

The First Targeted Treatment: Trofinetide (DAYBUE)

In 2023, Trofinetide (brand name DAYBUE) became the first FDA-approved drug for Rett syndrome in patients aged 2 years and older [1].

  • How it works: It is a synthetic version of a naturally occurring molecule in the brain that helps reduce inflammation and supports the health of synapses (the connections between brain cells) [3][4].
  • Efficacy: In clinical trials, it significantly improved core Rett symptoms, including mood, communication, and hand movements, as measured by both doctors and caregivers [1][5].
  • Side Effects & Safety: The most common side effect is diarrhea (occurring in about 80% of patients), followed by vomiting [1][6]. Weight loss was also a significant adverse event in pivotal trials [1][6]. Because poor growth and malnutrition are already major, life-threatening comorbidities in Rett syndrome, rigorous, ongoing weight monitoring by the care team is essential when taking this medication [1][7].

Overcoming Logistics: Insurance and Costs

Acquiring new therapeutics like Trofinetide, as well as specialized AAC (Augmentative and Alternative Communication) devices, can involve significant insurance hurdles. It is highly recommended to connect with a Medical Social Worker, Care Navigator, or Insurance Specialist early in your journey. Organizations like the IRSF can also provide guidance on navigating prior authorizations and appeals.

Multidisciplinary Standard of Care

Because Rett syndrome affects many systems in the body, a “team” approach is the gold standard [2][8]:

  • Physical Therapy (PT): Focuses on maintaining mobility, improving balance, and preventing joint stiffness [9].
  • Occupational Therapy (OT): Works on preserving hand function and finding ways to assist with daily living tasks [10].
  • Speech-Language Pathology (SLP): This is crucial for introducing AAC. Many children with Rett syndrome successfully use eye-tracking devices to speak and interact [11][12].

Managing Comorbidities

“Comorbidities” are other health conditions that often occur alongside Rett syndrome:

  • Epilepsy: Affects 50-90% of individuals [13]. It is treated with standard anti-seizure medications, though some experimental treatments like CBDV (cannabidivarin) have shown promise in trials [13][14].
  • GI Issues: Reflux and severe constipation are very common [15]. Proactive use of laxatives, stool softeners, or reflux medications is standard [16].
  • Scoliosis: Regular X-rays are needed to monitor the spine. If the curve becomes severe (often over 45 degrees), surgery may be recommended to help with breathing and comfort [17][10].
  • Breathing: While there is no specific pill for breathing irregularities (like breath-holding or hyperventilation), monitoring for triggers and ensuring good sleep hygiene is key [18].

The Future: Gene Therapy

We are currently in the middle of a “gene therapy revolution” for Rett syndrome. Several companies (including Taysha Gene Therapies and Neurogene) have started human clinical trials [19][20].

  • The Goal: To deliver a healthy copy of the MECP2 gene directly into the brain cells [19].
  • Finding Trials: You can actively look for clinical trials and research opportunities through ClinicalTrials.gov or by joining the IRSF Rett Syndrome Global Registry [19].

Staged Treatment Approach

Age/Stage Primary Focus of Care
Infancy (Stage 1) Early intervention (PT/OT), baseline genetic testing, and growth monitoring [8].
Regression (Stage 2) Managing irritability, starting AAC (eye-tracking), and beginning Trofinetide if eligible (age 2+) [1][11].
Plateau (Stage 3) Intensive communication training, monitoring for scoliosis, and managing seizures/GI issues [10][21].
Late Motor (Stage 4) Maintaining mobility through specialized equipment and managing orthopedic health [10][22].

Frequently Asked Questions

Is my child a candidate for DAYBUE (Trofinetide)?
Trofinetide (brand name DAYBUE) is FDA-approved for treating Rett syndrome in patients aged 2 years and older. Because it frequently causes side effects like diarrhea and weight loss, your doctor will need to monitor your child's weight and growth closely while on this medication.
How can we improve communication for a child with Rett syndrome?
Speech-language pathology plays a crucial role by introducing Augmentative and Alternative Communication (AAC). Many children with Rett syndrome successfully use eye-tracking devices to communicate their needs and interact with their families.
What are common comorbidities associated with Rett syndrome?
Individuals with Rett syndrome often experience other health conditions that require proactive management. The most common comorbidities include epilepsy, severe constipation, acid reflux, breathing irregularities, and scoliosis.
Is there a gene therapy available for Rett syndrome?
Researchers are currently conducting human clinical trials for Rett syndrome gene therapy. The goal of these experimental therapies is to deliver a healthy copy of the MECP2 gene directly into the brain cells to address the root cause of the condition.

Questions for Your Doctor

  • • Is my child a candidate for Trofinetide (DAYBUE), and what is your specific protocol for managing the likely side effects of diarrhea and weight loss?
  • • How can we integrate Augmentative and Alternative Communication (AAC), like eye-tracking, into my child's current speech therapy?
  • • What is the schedule for monitoring my child's spine for scoliosis, and at what point would we consider bracing or surgery?
  • • Can you help us coordinate a multidisciplinary team that includes a GI specialist familiar with Rett syndrome?
  • • Are there any active gene therapy trials (like Taysha or Neurogene) that my child might be eligible for based on their age and mutation?

Questions for You

  • • What are your child's most frequent or distressing symptoms right now (e.g., seizures, breathing issues, or digestive problems)? prioritizing these can help focus your next appointment.
  • • How is your child currently communicating their needs (e.g., eye gaze, sounds, or gestures)? Tracking these 'small' wins is vital.
  • • Have you noticed any new patterns in your child's breathing or sleep recently? Keeping a simple log can be very helpful for your doctor.
  • • What kind of support do you need to manage the daily physical demands of therapies and appointments? Asking for help is part of the treatment plan.

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Trofinetide for the treatment of Rett syndrome: a randomized phase 3 study.

    Neul JL, Percy AK, Benke TA, et al.

    Nature medicine 2023; (29(6)):1468-1475 doi:10.1038/s41591-023-02398-1.

    PMID: 37291210
  2. 2

    Rett syndrome: a review of clinical manifestations and therapeutic approaches.

    Bricker K, Vaughn BV

    Frontiers in sleep 2024; (3()):1373489 doi:10.3389/frsle.2024.1373489.

    PMID: 41424498
  3. 3

    Trofinetide: First Approval.

    Keam SJ

    Drugs 2023; (83(9)):819-824 doi:10.1007/s40265-023-01883-8.

    PMID: 37191913
  4. 4

    Trofinetide for Rett Syndrome: Highlights on the Development and Related Inventions of the First USFDA-Approved Treatment for Rare Pediatric Unmet Medical Need.

    Hudu SA, Elmigdadi F, Qtaitat AA, et al.

    Journal of clinical medicine 2023; (12(15)) doi:10.3390/jcm12155114.

    PMID: 37568516
  5. 5

    Profile of Trofinetide in the Treatment of Rett Syndrome: Design, Development and Potential Place in Therapy.

    Camillo L, Pozzi M, Bernardo P, et al.

    Drug design, development and therapy 2024; (18()):5023-5040 doi:10.2147/DDDT.S383133.

    PMID: 39525048
  6. 6

    Results from the phase 2/3 DAFFODIL study of trofinetide in girls aged 2-4 years with Rett syndrome.

    Percy AK, Ryther R, Marsh ED, et al.

    Med (New York, N.Y.) 2025; (6(6)):100608 doi:10.1016/j.medj.2025.100608.

    PMID: 40043705
  7. 7

    Managing Gastrointestinal Symptoms Resulting from Treatment with Trofinetide for Rett Syndrome: Caregiver and Nurse Perspectives.

    Moore R, Poulsen J, Reardon L, et al.

    Advances in therapy 2024; (41(4)):1305-1317 doi:10.1007/s12325-024-02782-4.

    PMID: 38378975
  8. 8

    Multidisciplinary Management of Rett Syndrome: Twenty Years' Experience.

    Vilvarajan S, McDonald M, Douglas L, et al.

    Genes 2023; (14(8)) doi:10.3390/genes14081607.

    PMID: 37628658
  9. 9

    Impact of a 12-month multifaceted neurological physiotherapy intervention on gross motor function in women with Rett syndrome.

    Kapel A, Kovacic T, Kos N, Velnar T

    Journal of integrative neuroscience 2022; (21(2)):59 doi:10.31083/j.jin2102059.

    PMID: 35364647
  10. 10

    Decline in gross motor skills in adult Rett syndrome; results from a Danish longitudinal study.

    Bisgaard AM, Wong K, Højfeldt AK, et al.

    American journal of medical genetics. Part A 2021; (185(12)):3683-3693 doi:10.1002/ajmg.a.62429.

    PMID: 34296518
  11. 11

    Teaching Requesting to Individuals with Rett Syndrome Using Alternative Augmentative Communication (AAC) Through Caregiver Coaching via Telehealth.

    Kolb RL, McComas JJ, Girtler SN, et al.

    Journal of developmental and physical disabilities 2023; (35(6)):1063-1090 doi:10.1007/s10882-023-09894-9.

    PMID: 38053943
  12. 12

    Communication Abilities, Assessment Procedures, and Intervention Approaches in Rett Syndrome: A Narrative Review.

    Voniati L, Papadopoulos A, Ziavra N, Tafiadis D

    Brain sciences 2025; (15(7)) doi:10.3390/brainsci15070753.

    PMID: 40722343
  13. 13

    Efficacy and safety of cannabidivarin treatment of epilepsy in girls with Rett syndrome: A phase 1 clinical trial.

    Hurley EN, Ellaway CJ, Johnson AM, et al.

    Epilepsia 2022; (63(7)):1736-1747 doi:10.1111/epi.17247.

    PMID: 35364618
  14. 14

    Epilepsy in classic Rett syndrome: Course and characteristics in adult age.

    Henriksen MW, Breck H, von Tetzchner S, et al.

    Epilepsy research 2018; (145()):134-139 doi:10.1016/j.eplepsyres.2018.06.012.

    PMID: 29966812
  15. 15

    Rett syndrome: think outside the (skull) box.

    Borloz E, Villard L, Roux JC

    Faculty reviews 2021; (10()):59 doi:10.12703/r/10-59.

    PMID: 34308425
  16. 16

    Recommendations for the management of gastrointestinal comorbidities with or without trofinetide use in Rett syndrome.

    Motil KJ, Beisang A, Smith-Hicks C, et al.

    Expert review of gastroenterology & hepatology 2024; (18(6)):227-237 doi:10.1080/17474124.2024.2368014.

    PMID: 38869952
  17. 17

    Scoliosis in RETT Syndrome: A National Referral Centre Experience.

    Menachem S, Hershkovich O, Ackshota N, et al.

    Clinical spine surgery 2023; (36(2)):E75-E79 doi:10.1097/BSD.0000000000001381.

    PMID: 35994037
  18. 18

    Sleep Disorders in Children with Rett Syndrome.

    Harner C, Gaffey TA, Sullivan SS, et al.

    Children (Basel, Switzerland) 2025; (12(7)) doi:10.3390/children12070869.

    PMID: 40723062
  19. 19

    The Efficacy of a Human-Ready miniMECP2 Gene Therapy in a Pre-Clinical Model of Rett Syndrome.

    Sadhu C, Lyons C, Oh J, et al.

    Genes 2023; (15(1)) doi:10.3390/genes15010031.

    PMID: 38254921
  20. 20

    Self-regulating gene therapy ameliorates phenotypes and overcomes gene dosage sensitivity in a mouse model of Rett syndrome.

    Ross PD, Gadalla KKE, Thomson SR, et al.

    Science translational medicine 2025; (17(792)):eadq3614 doi:10.1126/scitranslmed.adq3614.

    PMID: 40173263
  21. 21

    Trofinetide for the treatment of Rett syndrome: Results from the open-label extension LILAC study.

    Percy AK, Neul JL, Benke TA, et al.

    Med (New York, N.Y.) 2024; (5(9)):1178-1189.e3 doi:10.1016/j.medj.2024.05.018.

    PMID: 38917793
  22. 22

    4-hydroxynonenal protein adducts: Key mediator in Rett syndrome oxinflammation.

    Valacchi G, Pecorelli A, Cervellati C, Hayek J

    Free radical biology & medicine 2017; (111()):270-280 doi:10.1016/j.freeradbiomed.2016.12.045.

    PMID: 28063942

This information on Rett syndrome treatments and therapies is for educational purposes only. Always consult your child's neurologist and multidisciplinary care team for personalized medical advice and treatment planning.

Stay up to date

Get notified when new research about Rett syndrome is published.

No spam. Unsubscribe anytime.